Thanks Da Chopper, I've been waiting for the webcast to load the recording. One of the numb-nuts analysts thought he was the smartest person in the room and took valuable time. A few points I gleaned
Chrons is nowhere- still looking for a sweetspot Grossman posturing ( my hallucination) that if survival is set as the primary endpoint in the confirmatory trial for under 65's then you can stick your lack of understanding of MOA where the sun don't shine cause it will get approved. Si - going ahead with exploratory dosages for over 65's Si on Novartis- can't talk about the funding of the trial as waiting on the Novartis deal.
Reg
MSB Price at posting:
$1.71 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)